77,901 Pro-Dex, Inc. $PDEX Shares Acquired by Global Retirement Partners LLC

Global Retirement Partners LLC increased its position in shares of Pro-Dex, Inc. (NASDAQ:PDEX – Free Report) by 7,790.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,901 shares of the medical instruments supplier’s stock after acquiring an additional 77,901 shares during the quarter. Global Retirement Partners LLC’s holdings in Pro-Dex were worth $5,444,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. grew its holdings in Pro-Dex by 1,443.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 11,191 shares of the medical instruments supplier’s stock worth $772,000 after acquiring an additional 10,466 shares during the last quarter. Ritholtz Wealth Management increased its position in shares of Pro-Dex by 57.7% in the third quarter. Ritholtz Wealth Management now owns 7,288 shares of the medical instruments supplier’s stock valued at $503,000 after acquiring an additional 2,668 shares during the period. Pekin Hardy Strauss Inc. raised its stake in shares of Pro-Dex by 38.2% during the third quarter. Pekin Hardy Strauss Inc. now owns 22,800 shares of the medical instruments supplier’s stock valued at $1,573,000 after acquiring an additional 6,300 shares during the last quarter. James Investment Research Inc. bought a new position in shares of Pro-Dex during the third quarter valued at about $207,000. Finally, Ellsworth Advisors LLC bought a new position in shares of Pro-Dex during the third quarter valued at about $1,166,000. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Weiss Ratings raised Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, November 10th. Ascendiant Capital Markets raised their price objective on shares of Pro-Dex from $74.00 to $80.00 and gave the company a “buy” rating in a research note on Monday. Finally, Zacks Research downgraded shares of Pro-Dex from a “strong-buy” rating to a “hold” rating in a report on Monday, November 9th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.00.

Check Out Our Latest Report on Pro-Dex

Insider Buying and Selling

In related news, CEO Kirk Richard Lee Van, Jr. sold 19,235 shares of the stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $60.58, for a total value of $1,165,256.30. Following the completion of the sale, the chief executive officer directly owned 79,993 shares of the company’s stock, valued at approximately $4,845,975.94. This represents a 19.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $61.30, for a total transaction of $140,990.00. Following the sale, the chief financial officer owned 21,870 shares in the company, valued at approximately $1,340,631. The trade was a 9.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 22,300 shares of company stock valued at $1,351,657. 48.00% of the stock is currently owned by corporate insiders.

Pro-Dex Price Performance

NASDAQ PDEX opened at $63.94 on Thursday. The business’s fifty day moving average is $64.84 and its 200 day moving average is $58.03. Pro-Dex, Inc. has a fifty-two week low of $28.81 and a fifty-two week high of $77.00. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.49 and a current ratio of 4.19. The company has a market capitalization of $204.61 million, a PE ratio of 16.97 and a beta of 0.12.

Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pro-Dex had a return on equity of 26.18% and a net margin of 15.12%. The business had revenue of $20.56 million during the quarter, compared to analysts’ expectations of $20.40 million. Sell-side analysts predict that Pro-Dex, Inc. will post 3.09 earnings per share for the current year.

About Pro-Dex

(Free Report)

Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.

Further Reading

Want to see what other hedge funds are holding PDEX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pro-Dex, Inc. (NASDAQ:PDEX – Free Report).

Institutional Ownership by Quarter for Pro-Dex (NASDAQ:PDEX)

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.